期刊文献+

氨氯地平对心衰大鼠体内地高辛药动学的影响 被引量:1

Effect of amlodipine on the pharmacokinetics of digoxin in rats with heart failure
暂未订购
导出
摘要 目的:研究氨氯地平与地高辛合用对心衰大鼠体内地高辛的药动学影响。方法:采用腹主动脉狭窄方法制作大鼠心衰模型,实验分地高辛单用组和地高辛与氨氯地平合用组,采用荧光偏振免疫法检测血浆中地高辛的浓度,药-时数据经DAS ver1.0软件处理,确定单用组与合用组的药动学参数。结果:合用氨氯地平后,地高辛的达峰时间由0.67h推迟为1.00h,AUC0-24由(15.2±6.0)μg.L-1.h减少为(13.6±4.1)μg.L-1.h,经配对t检验,2组间主要药动学参数T1/2α,T1/2β,AUC0-24,CL/F,Cmax均无显著性差异(P>0.05)。结论:氨氯地平对心衰大鼠体内地高辛的药动学过程无影响。 OBJECTIVE To study the effect of amlodipine on the pharmacokinetics of digoxin in rats with heart failure. METHODS The model of heart failure was made by applying abdominal artery constriction. Wistar rats were randomly divided into digoxin group and digoxin combined with amlodipine group. Concentration of digoxin in plasma was determined by Fluorescence Polarization Immunoassay. The pharmacokinetic parameters were calculated by DAS vet 1.0. RESULTS Compared with digoxin group, the Tmax of digoxin combined with amlodipine group was changed from 0. 67 h to 1.00 h, the AUC0-24was decreased from ( 15.24 ± 6. 05 ) ng · L^-1 · h to ( 13.62 ± 4. 08 ) ng · L^-1 · h. With paired T-test, t1/2α, t1/2β, AUC0-24 , CL/F, Cmax were no obvious different between two groups. CONCLUSION Amlodipine had no influence on pharmacokinetic parameters of digoxin in rats with heart failure.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2008年第5期338-340,共3页 Chinese Journal of Hospital Pharmacy
关键词 氨氯地平 地高辛 心衰大鼠 药动学 amlodipine digoxin rats with heart failure pharmacokinetic
  • 相关文献

参考文献4

  • 1周小丹.钙拮抗剂氨氯地平与临床[J].西北药学杂志,2000,15(2):84-85. 被引量:12
  • 2Janice B, Schwartz. Effects of amLodipine on steady-state digoxin concentrations and renal digoxin clearance[J]. Journal of Cardiovascular Pharmacology, 1988,12 ( 1 ) : 1- 5.
  • 3赵英强,孙兰军,徐强,李慧臻,王保和.慢性充血性心力衰竭大鼠动物模型制备[J].天津中医药,2004,21(4):318-321. 被引量:19
  • 4Tonnessen T. christensen G, Qie E, et al. Increased cardiac expression of endothelin -1 mRNA in ischemic heart failure in rats[J]. Cardiovascular Research, 1997,33 : 601-610.

二级参考文献14

  • 1林金秀,陈达光,黄端,郑舒亮.氨氯地平对高血压病人胰岛素敏感性的影响[J].中华心血管病杂志,1996,24(2):97-100. 被引量:26
  • 2娄建石,张海波,刘艳霞,朱险峰,张才丽.无创性心功能血流动力学计算机实时监测系统[J].中国药理学通报,1996,12(1):91-95. 被引量:8
  • 3汪谦.现代医学实验方法[M].北京:人民卫生出版社,1998.914.
  • 4RodriguezN,DominguezB.Experiencewithamlodipine(Norvasc)inthemanagementofarterialhypertension.RevMedPanama,1993,18(3):233
  • 5ZichaJ.Personalclinicalexperienceinthetreatmentofarterialhypertensionusingamoldipine.VnitrLek,1996,42(3):153
  • 6KlonerRA,SowersJR,DibonaGF,etal.Effectofamlodipineonleftventricularmassintheamlodipinecardiovascularcommunitytrial.JCardiovascPharmacol,1995,26(3):471
  • 7BeckermanB.Anopenmulticenterofsymptomaticmyocardialischimera.JCardiovascpharmacol,1991,17(Suppl1):61
  • 8ChahineRA,FeldmanRL,GilesTD,etal.Randomizedplacebo-controlledtrialofamlodipineinvasospasticangina.JAnCollCardiol,1993,21:1365
  • 9TaylorSH.Amoldipineinpost-infarctionangina.Cardiology,1992,80(Suppl1):26
  • 10JennisonSH,Millerlw.Whattotrywhilecongestiveheartfailurepatientsarestillambulatory.Postgrad-Med,1993,94(5):66

共引文献29

同被引文献6

  • 1钱元恕,莫岚,兰雁飞,王其南.环丙沙星、氧氟沙星和诺氟沙星对大鼠肝微粒体混合功能氧化酶的作用[J].中国抗生素杂志,1994,19(6):459-463. 被引量:14
  • 2莫岚,钱元恕,王其南,许炜.培氟沙星对大鼠肝微粒体酶系的抑制作用[J].新药与临床,1995,14(1):15-17. 被引量:10
  • 3Gibbons RJJ, Ant-man EM, Alpert JS, et al. ACC/AHA/ESC guidelines for the management of patients with artial fibrillation[J ]. Circulation, 2001, 104(17) : 2118.
  • 4Zangar RC, Benson JM, Burnett VL. Cytochrome P450 2E1 is the primary enzyme responsible for low-dose carbon tetrachloride metabolism in human liver microsome [J]. Chem Biol Interact, 2000, 125(3) :233-243.
  • 5Lin SW, Jean WC, Peng FC. Cytochrome P-4503A1 catalyzes the formation of MA1 from territrem a in liver microsomes of 7 week-old female Wistar rats[J]. J Toxicol Environ Health A, 2003, 66(5) :453-467.
  • 6张均田.现代药理实验方法[M].北京:北京医科大学中国协和医科大学联合出版社,1998.1151.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部